Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Up 0.8 %

CARA stock opened at $4.90 on Monday. Cara Therapeutics has a 1-year low of $2.71 and a 1-year high of $10.44. The business’s 50-day moving average price is $5.05 and its two-hundred day moving average price is $4.37. The firm has a market cap of $22.41 million, a PE ratio of -0.23 and a beta of 0.41.

Institutional Trading of Cara Therapeutics

Several hedge funds have recently bought and sold shares of CARA. Rockefeller Capital Management L.P. bought a new stake in shares of Cara Therapeutics during the fourth quarter worth $953,000. XTX Topco Ltd bought a new position in Cara Therapeutics during the 3rd quarter worth about $29,000. Shay Capital LLC acquired a new stake in shares of Cara Therapeutics in the 4th quarter valued at about $524,000. Curi RMB Capital LLC acquired a new position in shares of Cara Therapeutics during the fourth quarter worth about $277,000. Finally, FMR LLC grew its holdings in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.